Clinical trials
Liver Cell Carcinoma clinical trials
Below are recruiting liver cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 445 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06572514RecruitingPhase 1/Phase 2
Lower radiation after chemo-immunotherapy for head and neck cancer
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07627347Recruiting
Anlotinib and Bemocizumab for Early Esophageal Cancer
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06240689RecruitingPhase 2
Immune maintenance therapy after chemoradiotherapy for head and neck cancer
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hangzhou, ZhejiangAges 18–75 - NCT05096390RecruitingPhase 2
Axitinib plus pembrolizumab for first metastatic kidney cancer
This Phase 2 trial studies whether combining axitinib and pembrolizumab can shrink and control metastatic or inoperable type 2 or mixed papillary kidney cancer. It may help by blocking cancer growth signals and boosting the immune system to attack the cancer.
AngersAges 18 years+ - NCT07565740RecruitingPhase 1
Vaccine plus immunotherapy for newly diagnosed HPV-positive throat cancer
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
Chengdu, SichuanAges 18 years+ - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT07611825RecruitingPhase 2
Gut Bacteria Treatment for Advanced Kidney Cancer Resistant to Immunotherapy
This study tests whether modifying your gut bacteria can help immunotherapy work again in advanced kidney cancer that has stopped responding to initial immune-checkpoint inhibitor treatment. Researchers will give you a special bacterial preparation along with a new immunotherapy drug to see if this combination can slow or shrink your cancer.
Nanjing, JiangsuAges 18–90 - NCT03734952Recruiting
Radiation after esophagus surgery for stage II–III cancer
This study looks at whether giving radiation after surgery (after chemo and radiation before surgery) can improve outcomes for people with squamous cell esophagus cancer in the chest. You may be considered if you are well enough for treatment and your cancer has not spread.
Fuzhou, FujianAges 18–65 - NCT07266480RecruitingPhase 2
Adalimumab after surgery for esophageal cancer
This trial tests whether adding adalimumab (a medicine that helps the immune system) after surgery can prevent esophageal cancer from coming back. It's for people who have already had their cancer completely removed by surgery.
Shijiazhuang, HebeiAges 18 years+ - NCT05868174RecruitingPhase 1
Testing a targeted radiation drug plus a DNA repair blocker
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
North Ryde, New South WalesAges 18 years+ - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT06052839RecruitingPhase 2
Pulsed chemo plus pembrolizumab for head and neck cancer
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07064330Recruiting
Blood test for immune markers in skin cancer patients on cemiplimab
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
Salamanca, SalamancaAges 18 years+ - NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT07398664RecruitingPhase 2
H101 virus plus TACE for recurrent head and neck cancer
This trial tests combining a cancer-killing virus (H101) with a procedure that delivers chemo directly to the tumor (TACE) for people with advanced head and neck cancers that have not responded to at least two standard treatments. It aims to see if this combination can help shrink tumors and improve outcomes.
Chengdu, SichuanAges 18–80 - NCT03114462RecruitingPhase 1
Study of focused radiation for laryngeal cancer
This Phase 1 study tests a precise type of radiation treatment for people with certain stages of laryngeal (voice box) squamous cell cancer. The goal is to see how safe the treatment is and how well it may work in shrinking or controlling the cancer while aiming to preserve the larynx.
Houston, TexasAges 18 years+ - NCT03736863RecruitingPhase 2
Testing combinations of medicines for advanced throat cancer
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
Zhengzhou, HenanAges 18–75 - NCT04857164RecruitingPhase 2
Pembrolizumab plus chemotherapy for recurrent or metastatic throat cancer
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07697859Recruiting
Immunotherapy with local treatment for limited spread esophageal cancer
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05030597Recruiting
PET scans targeting FAP for oral cancer and recurrence
This trial uses a special PET scan that targets a substance called FAP to better find oral squamous cell cancer and check for recurrence. It may help doctors see where cancer activity is and guide treatment planning, especially around surgery and (for some people) neoadjuvant therapy before surgery.
Wuhan, HubeiAges 18–70 - NCT05069857RecruitingPhase 2
New pre-surgery treatment tailored to cancer markers in mouth cancer
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05125055RecruitingPhase 2/Phase 3
Test new throat cancer treatment before surgery
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05198154Recruiting
Blood test to watch lung cancer risk after immunotherapy
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
Changsha, HunanAges 18 years+
Hear when a new Liver Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cell carcinoma?
- Yes. Clin2 currently lists 445 recruiting liver cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.